ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 42.6% in December

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 360,300 shares, a decline of 42.6% from the December 15th total of 628,000 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average daily volume of 266,100 shares, the days-to-cover ratio is currently 1.4 days.

ABVC BioPharma Stock Performance

Shares of ABVC stock opened at $0.52 on Wednesday. The stock’s fifty day moving average is $0.54 and its 200-day moving average is $0.63. ABVC BioPharma has a 52 week low of $0.41 and a 52 week high of $1.73. The stock has a market capitalization of $6.69 million, a PE ratio of -0.60 and a beta of 0.70.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.